Lestaurtinib (CEP701) is a JAK2 Inhibitor That Suppresses JAK2/STAT5 Signaling and the Proliferation of Primary Erythroid Cells from Patients with Myeloproliferative Disorders

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2007 Nov 7

PMID 17984313

Citations 107

Authors

Elizabeth O Hexner

Cynthia Serdikoff

Mahfuza Jan

Cezary R Swider

Candy Robinson

Shi Yang

Thelma Angeles

Stephen G Emerson

Martin Carroll

Bruce Ruggeri

Pawel Dobrzanski

Affiliations

Soon will be listed here.

Abstract

Recent studies have demonstrated that patients with myeloproliferative disorders (MPDs) frequently have acquired activating mutations in the JAK2 tyrosine kinase. A multikinase screen determined that lestaurtinib (formerly known as CEP-701) inhibits wild type JAK2 kinase activity with a concentration that inhibits response by 50% (IC(50)) of 1 nM in vitro. We hypothesized that lestaurtinib would inhibit mutant JAK2 kinase activity and suppress the growth of cells from patients with MPDs. We found that lestaurtinib inhibits the growth of HEL92.1.7 cells, which are dependent on mutant JAK2 activity for growth in vitro and in xenograft models. Erythroid cells expanded from primary CD34(+) cells from patients with MPDs were inhibited by lestaurtinib at concentrations of 100 nM or more in 15 of 18 subjects, with concomitant inhibition of phosphorylation of STAT5 and other downstream effectors of JAK2. By contrast, growth of erythroid cells derived from 3 healthy controls was not significantly inhibited. These results demonstrate that lestaurtinib, in clinically achievable concentrations, inhibits proliferation and JAK2/STAT5 signaling in cells from patients with MPDs, and therefore holds promise as a therapeutic agent for patients with these disorders.

Citing Articles

Weighted Gene Co-expression Network Analysis of the Inflammatory Wnt Signaling Reveals Biomarkers Related to Bone Formation.

Yadalam P, Ramadoss R, Suresh R Cureus. 2024; 16(6):e63510.

PMID: 39081453 PMC: 11288288. DOI: 10.7759/cureus.63510.

Discovery of -(4-(Aminomethyl)phenyl)-5-methylpyrimidin-2-amine Derivatives as Potent and Selective JAK2 Inhibitors.

Tian Y, Qin S, Zhang F, Luo J, He X, Sun Y ACS Med Chem Lett. 2023; 14(8):1113-1121.

PMID: 37583815 PMC: 10424325. DOI: 10.1021/acsmedchemlett.3c00251.

RUNX1 loss renders hematopoietic and leukemic cells dependent on IL-3 and sensitive to JAK inhibition.

Fan A, Nakauchi Y, Bai L, Azizi A, Nuno K, Zhao F J Clin Invest. 2023; 133(19).

PMID: 37581927 PMC: 10541186. DOI: 10.1172/JCI167053.

Genetic lesions and targeted therapy in Hodgkin lymphoma.

Li Z, Mu W, Xiao M Ther Adv Hematol. 2023; 14:20406207221149245.

PMID: 36654739 PMC: 9841868. DOI: 10.1177/20406207221149245.

Lestaurtinib induces DNA damage that is related to estrogen receptor activation.

Ooka M, Yang S, Zhang L, Kojima K, Huang R, Hirota K Curr Res Toxicol. 2023; 4:100102.

PMID: 36619290 PMC: 9816669. DOI: 10.1016/j.crtox.2022.100102.

References

Baxter E, Scott L, Campbell P, East C, Fourouclas N, Swanton S . Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005; 365(9464):1054-61. DOI: 10.1016/S0140-6736(05)71142-9. View

James C, Ugo V, Le Couedic J, Staerk J, Delhommeau F, Lacout C . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005; 434(7037):1144-8. DOI: 10.1038/nature03546. View

Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C . Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002; 346(9):645-52. DOI: 10.1056/NEJMoa011573. View

Tehranchi R, Invernizzi R, Grandien A, Zhivotovsky B, Fadeel B, Forsblom A . Aberrant mitochondrial iron distribution and maturation arrest characterize early erythroid precursors in low-risk myelodysplastic syndromes. Blood. 2005; 106(1):247-53. DOI: 10.1182/blood-2004-12-4649. View

Quentmeier H, MacLeod R, Zaborski M, Drexler H . JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006; 20(3):471-6. DOI: 10.1038/sj.leu.2404081. View

Nowell P, HUNGERFORD D . Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst. 1960; 25:85-109. View

Pardanani A, Levine R, Lasho T, Pikman Y, Mesa R, Wadleigh M . MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006; 108(10):3472-6. DOI: 10.1182/blood-2006-04-018879. View

OBrien S, Guilhot F, Larson R, Gathmann I, Baccarani M, Cervantes F . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004. DOI: 10.1056/NEJMoa022457. View

10.

Druker B, Tamura S, Buchdunger E, Ohno S, Segal G, Fanning S . Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2(5):561-6. DOI: 10.1038/nm0596-561. View

11.

Demetri G, von Mehren M, Blanke C, Van Den Abbeele A, Eisenberg B, Roberts P . Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002; 347(7):472-80. DOI: 10.1056/NEJMoa020461. View

12.

OShea J, Gadina M, Schreiber R . Cytokine signaling in 2002: new surprises in the Jak/Stat pathway. Cell. 2002; 109 Suppl:S121-31. DOI: 10.1016/s0092-8674(02)00701-8. View

13.

Pikman Y, Lee B, Mercher T, McDowell E, Ebert B, Gozo M . MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006; 3(7):e270. PMC: 1502153. DOI: 10.1371/journal.pmed.0030270. View

14.

Cools J, DeAngelo D, Gotlib J, Stover E, Legare R, Cortes J . A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003; 348(13):1201-14. DOI: 10.1056/NEJMoa025217. View

15.

Ratajczak J, Majka M, Kijowski J, BAJ M, Pan Z, Marquez L . Biological significance of MAPK, AKT and JAK-STAT protein activation by various erythropoietic factors in normal human early erythroid cells. Br J Haematol. 2001; 115(1):195-204. DOI: 10.1046/j.1365-2141.2001.03058.x. View

16.

Loken M, Shah V, Dattilio K, Civin C . Flow cytometric analysis of human bone marrow: I. Normal erythroid development. Blood. 1987; 69(1):255-63. View

17.

Lacout C, Pisani D, Tulliez M, Gachelin F, Vainchenker W, Villeval J . JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis. Blood. 2006; 108(5):1652-60. DOI: 10.1182/blood-2006-02-002030. View

18.

Smith B, Levis M, Beran M, Giles F, Kantarjian H, Berg K . Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004; 103(10):3669-76. DOI: 10.1182/blood-2003-11-3775. View

19.

Benito A, Silva M, Grillot D, Nunez G, Fernandez-Luna J . Apoptosis induced by erythroid differentiation of human leukemia cell lines is inhibited by Bcl-XL. Blood. 1996; 87(9):3837-43. View

20.

Wernig G, Mercher T, Okabe R, Levine R, Lee B, Gilliland D . Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model. Blood. 2006; 107(11):4274-81. PMC: 1895786. DOI: 10.1182/blood-2005-12-4824. View